| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Alemtuzumab biosimilar (Zhangjiang Biotechnology) | Phase 2 Clinical | Shanghai Zhangjiang Biotechnology Co Ltd | Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| ALLO-647 | ALLO-647 | Phase 2 Clinical | Allogene Therapeutics Inc | Lymphoma, B-Cell; Carcinoma, Renal Cell; Multiple Myeloma; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Recombinant anti-CD52 humanized monoclonal antibody (Lanzhou Institute Of Biological Products/Shanghai Taiyin Biotechnology) | Phase 1 Clinical | Lanzhou Institute Of Biological Products Co Ltd, Shanghai Taiyin Biotechnology Co Ltd | Leukemia, B-Cell; Leukemia, Prolymphocytic, T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, Prolymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| Alemtuzumab biosimilar(BioXpress) | BX-1523; BXT-1523 | Clinical | Bioxpress Therapeutics Sa | Multiple Sclerosis; Leukemia, B-Cell | Details |
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Alemtuzumab | LDP-03; GZ-402673 | Approved | Genzyme Corp, Bayer AG | Campath, Lemtrada, MabCampath | United States | Multiple Sclerosis | Genzyme Corp | 2001-05-07 | Myositis, Inclusion Body; Leukemia, Lymphocytic, Chronic, B-Cell; Mycosis Fungoides; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Waldenstrom Macroglobulinemia; Lymphoma; Leukemia, Prolymphocytic, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell; Lymphoproliferative Disorders; Peritoneal Neoplasms; Sezary Syndrome; Pancytopenia; Lymphoma, T-Cell, Peripheral; Multiple Sclerosis; Rejection of organ transplantation; Leukemia-Lymphoma, Adult T-Cell; Myelodysplastic Syndromes; Hodgkin Disease; Graft vs Host Disease; Kidney Diseases; Rejection of renal transplantation; Hematologic Neoplasms; Ovarian Neoplasms; Diabetes Mellitus, Type 1; Bone marrow transplant rejection; Leukemia; Multiple Sclerosis, Relapsing-Remitting | Details |




